Takahiro Kasamatsu

Summary

Affiliation: National Cancer Center
Country: Japan

Publications

  1. ncbi Early invasive adenocarcinoma of the uterine cervix: criteria for nonradical surgical treatment
    Takahiro Kasamatsu
    Division of Gynecology, National Cancer Center Hospital, 5 1 1 Tsujkiji, Chuo Ku, Tokyo 104 0045, Japan
    Gynecol Oncol 85:327-32. 2002
  2. ncbi Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus
    T Kasamatsu
    Division of Gynecology, National Cancer Center Hospital, Tokyo, Japan
    Br J Cancer 88:245-50. 2003
  3. ncbi Surgical treatment for neuroendocrine carcinoma of the uterine cervix
    T Kasamatsu
    Division of Gynecology, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Int J Gynaecol Obstet 99:225-8. 2007
  4. ncbi Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation
    Takahiro Kasamatsu
    Division of Gynecology, National Cancer Center Hospital, 5 1 1, Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Gynecol Oncol 114:69-74. 2009
  5. ncbi Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix
    T Kasamatsu
    Division of Gynecology, National Cancer Center Hospital, Tokyo, Japan
    Br J Cancer 100:1400-5. 2009
  6. ncbi Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervix
    Takahiro Kasamatsu
    Division of Gynecology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Gynecol Oncol 115:488-92. 2009
  7. ncbi Clinical aspects and prognosis of pelvic recurrence of cervical carcinoma
    T Kasamatsu
    Division of Gynecology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Int J Gynaecol Obstet 89:39-44. 2005
  8. ncbi Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy
    Shin Nishio
    Division of Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    J Cancer Res Clin Oncol 135:551-7. 2009
  9. ncbi Prognostic impact of the history of breast cancer and of hormone therapy in uterine carcinosarcoma
    Takashi Uehara
    Division of Gynecologic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Int J Gynecol Cancer 22:280-5. 2012
  10. ncbi Combination of squamous cell carcinoma-antigen, carcinoembryonic antigen, and carbohydrate antigen 19-9 predicts positive pelvic lymph nodes and parametrial involvement in early stage squamous cell carcinoma of the uterine cervix
    Shun ichi Ikeda
    Division of Gynecology, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    J Obstet Gynaecol Res 38:1260-5. 2012

Detail Information

Publications27

  1. ncbi Early invasive adenocarcinoma of the uterine cervix: criteria for nonradical surgical treatment
    Takahiro Kasamatsu
    Division of Gynecology, National Cancer Center Hospital, 5 1 1 Tsujkiji, Chuo Ku, Tokyo 104 0045, Japan
    Gynecol Oncol 85:327-32. 2002
    ..This retrospective study was undertaken to identify selection criteria for nonradical surgery for early invasive adenocarcinoma of the uterine cervix...
  2. ncbi Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus
    T Kasamatsu
    Division of Gynecology, National Cancer Center Hospital, Tokyo, Japan
    Br J Cancer 88:245-50. 2003
    ....
  3. ncbi Surgical treatment for neuroendocrine carcinoma of the uterine cervix
    T Kasamatsu
    Division of Gynecology, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Int J Gynaecol Obstet 99:225-8. 2007
    ..To identify the best operative approach for neuroendocrine cervical carcinoma (NECC)...
  4. ncbi Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation
    Takahiro Kasamatsu
    Division of Gynecology, National Cancer Center Hospital, 5 1 1, Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Gynecol Oncol 114:69-74. 2009
    ..To clarify the clinicopathological features and prognostic factors of patients with FIGO stage IIB cervical cancer who were treated with radical hysterectomy...
  5. ncbi Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix
    T Kasamatsu
    Division of Gynecology, National Cancer Center Hospital, Tokyo, Japan
    Br J Cancer 100:1400-5. 2009
    ..FIGO stage I-IIB patients with AC or SCC, who underwent radical hysterectomy, have similar prognosis and spread pattern, but different ovarian metastasis rates...
  6. ncbi Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervix
    Takahiro Kasamatsu
    Division of Gynecology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Gynecol Oncol 115:488-92. 2009
    ..A retrospective analysis was carried out to evaluate the prognostic significance of peritoneal cytology in cervical adenocarcinoma...
  7. ncbi Clinical aspects and prognosis of pelvic recurrence of cervical carcinoma
    T Kasamatsu
    Division of Gynecology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Int J Gynaecol Obstet 89:39-44. 2005
    ..To identify which patients with locally recurrent cervical carcinoma are potentially curable...
  8. ncbi Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy
    Shin Nishio
    Division of Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    J Cancer Res Clin Oncol 135:551-7. 2009
    ..Limited information is available regarding the usefulness of third-line chemotherapy for recurrent ovarian, fallopian tube, and primary peritoneal cancer treated with platinum-taxane regimens as first-line therapy...
  9. ncbi Prognostic impact of the history of breast cancer and of hormone therapy in uterine carcinosarcoma
    Takashi Uehara
    Division of Gynecologic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Int J Gynecol Cancer 22:280-5. 2012
    ..The aim of this study was to investigate the characteristics and prognosis of patients with UCS after BC and hormone therapy...
  10. ncbi Combination of squamous cell carcinoma-antigen, carcinoembryonic antigen, and carbohydrate antigen 19-9 predicts positive pelvic lymph nodes and parametrial involvement in early stage squamous cell carcinoma of the uterine cervix
    Shun ichi Ikeda
    Division of Gynecology, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    J Obstet Gynaecol Res 38:1260-5. 2012
    ....
  11. ncbi Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma
    Shinichi Togami
    Division of Gynecology, National Cancer Center Hospital, Tokyo, Japan
    Cancer Sci 103:926-32. 2012
    ..022, P = 0.018, and P = 0.01, respectively), but HR was the only independent factor associated with OS (P = 0.044). Thus, HER2 and HR are prognostic variables in UPSC, with HR an independent prognostic factor for OS...
  12. ncbi Serous adenocarcinoma of the uterine cervix: a clinicopathological study of 12 cases and a review of the literature
    Shinichi Togami
    Division of Gynecology, National Cancer Center Hospital, Tokyo, Japan
    Gynecol Obstet Invest 73:26-31. 2012
    ..To determine the clinicopathological characteristics and potentially associated outcomes in patients diagnosed with serous adenocarcinoma of the uterine cervix...
  13. ncbi A rare case of recurrent ovarian cancer presenting as a round ligament metastasis
    Shinichi Togami
    Division of Gynecology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    World J Surg Oncol 9:144. 2011
    ....
  14. ncbi Different pattern of loss of heterozygosity among endocervical-type adenocarcinoma, endometrioid-type adenocarcinoma and adenoma malignum of the uterine cervix
    Hitoshi Tsuda
    Pathology Division, National Cancer Research Institute and Hospital, Tokyo, Japan
    Int J Cancer 98:713-7. 2002
    ..Chromosomal arms that are prone to show LOH appeared to differ between the 2 types of cervical adenocarcinoma. We could suggest that "pure" adenoma malignum is of clonal and neoplastic nature in view of the detection of LOH...
  15. ncbi Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer
    Ryoko Kikuchi
    Department of Molecular Cytogenetics, Medical Research Institute and School of Biomedical Science, Tokyo Medical and Dental University, Tokyo, Japan
    Cancer Res 68:5067-75. 2008
    ..These results suggest that, at least partly, epigenetic silencing by hypermethylation of the ANGPTL2 promoter leads to a loss of ANGPTL2 function, which may be a factor in the carcinogenesis of OC in a stage-dependent manner...
  16. ncbi A case of diffuse retroperitoneal lymphangioma with endometrial cancer
    Michihiro Tanikawa
    Gynecology Division, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 38:507. 2008
  17. ncbi Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma
    Shin Nishio
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Oncol Rep 19:497-503. 2008
    ..03) were independent prognostic factors of survival, respectively. Poor PS and non-chemotherapy groups were found to have poor prognosis in patients with stage IVb CC. Chemotherapy may improve the survival for stage IVb CC...
  18. ncbi Difference in cytoplasmic localization pattern of neutral mucin among lobular endocervical glandular hyperplasia, adenoma malignum, and common adenocarcinoma of the uterine cervix
    Isamu Hayashi
    Department of Clinical Laboratory, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, 104 0045 Tokyo, Japan
    Virchows Arch 443:752-60. 2003
    ..The examination of cytoplasmic localization of neutral mucin might be applicable, not only to differential diagnosis between LEGH and CxAd, including MDA, but also to estimate clinical aggressiveness of CxAd...
  19. ncbi Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma
    Morio Sawada
    Department of Gynecology, National Cancer Center Hospital, Tokyo, and Department of Pathology II, National Defense Medical College, Tokorozawa
    Cancer Sci 94:986-91. 2003
    ..Structural and/or numerical alterations of chromosomes might be in part involved in EGFR and/or HER-2 overexpression in this tumor type...
  20. ncbi A case of vaginal clear cell adenocarcinoma complicated with congenital anomalies of the genitourinary tract and metanephric remnant without prenatal diethylstilbestrol exposure
    Takashi Uehara
    Gynecology Division, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    J Obstet Gynaecol Res 36:681-5. 2010
    ..The adenosis was also supposed to occur as a congenital basis, together with genitourinary tract anomalies. Relations between congenital anomalies of the genitourinary tract and vaginal adenocarcinoma were suspected, resultantly...
  21. ncbi Versatile lotus petal flap for vulvoperineal reconstruction after gynecological ablative surgery
    Morio Sawada
    Division of Gynecology, National Cancer Center Hospital, Tokyo, Japan
    Gynecol Oncol 95:330-5. 2004
    ..The objective of the present work was to assess the efficacy and complications of the use of the lotus petal flap in the vulvoperineal reconstruction among female patients treated for vulvar malignancies...
  22. ncbi A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy
    Kan Yonemori
    Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Cancer 104:1204-12. 2005
    ..CONCLUSIONS: The recommended dose for the Phase II study was irinotecan 60 mg/m(2) on Days 1, 8, and 15 with carboplatin 5 mg/mL . minute on Day 1 repeated every 4 weeks...
  23. ncbi Serous adenocarcinoma of the retroperitoneum, as a type of multifocal müllerian carcinoma
    Ayaka Iura
    Breast and Medical Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Int J Clin Oncol 14:254-7. 2009
    ..The patient had been taking conjugated estrogen for 10 years, suggesting that long-term estrogen stimulation may have contributed to the progression of the tumors...
  24. ncbi [Registration of gynecologic malignancy in Japan]
    Takahiro Kasamatsu
    Division of Gynecology, National Cancer Center Hospital
    Nippon Rinsho 62:44-8. 2004
  25. ncbi Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma
    Shin Nishio
    Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    Cancer Lett 264:36-43. 2008
    ..Our results suggest that increased expression of Cap43 is associated with angiogenesis and may be a poor prognostic indicator in women with cervical adenocarcinoma...
  26. ncbi Reproducible and clinically meaningful differential diagnosis is possible between lobular endocervical glandular hyperplasia and 'adenoma malignum' based on common histopathological criteria
    Hitoshi Tsuda
    Department of Pathology II, National Defense Medical College, Tokorozawa, Japan
    Pathol Int 55:412-8. 2005
    ..01). It is clearly shown that reproducible differential diagnosis is possible between LEGH, LEGH with AIS, and MDA and that such a differentiation is clinically meaningful...
  27. ncbi Interobserver variation in the diagnosis of adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix
    Hitoshi Tsuda
    Department of Pathology II, National Defense Medical College, Tokorozawa, Saitama, Japan
    Pathol Int 53:440-9. 2003
    ....